231 related articles for article (PubMed ID: 2309001)
21. The effect of a combined purging with mafosfamide and hyperthermia on murine haemopoietic stem cells and leukaemogenic cells.
Gidáli J; Fehér I
Bone Marrow Transplant; 1992 Dec; 10(6):479-83. PubMed ID: 1490197
[TBL] [Abstract][Full Text] [Related]
22. The suppressive influences of human tumor necrosis factors on bone marrow hematopoietic progenitor cells from normal donors and patients with leukemia: synergism of tumor necrosis factor and interferon-gamma.
Broxmeyer HE; Williams DE; Lu L; Cooper S; Anderson SL; Beyer GS; Hoffman R; Rubin BY
J Immunol; 1986 Jun; 136(12):4487-95. PubMed ID: 3086433
[TBL] [Abstract][Full Text] [Related]
23. Combination of N,N',N"-triethylenethiophosphoramide and cyclophosphamide in vitro and in vivo.
Teicher BA; Holden SA; Cucchi CA; Cathcart KN; Korbut TT; Flatow JL; Frei E
Cancer Res; 1988 Jan; 48(1):94-100. PubMed ID: 3121169
[TBL] [Abstract][Full Text] [Related]
24. Comparative cytotoxicity of various drug combinations for human leukemic cells and normal hematopoietic precursors.
Chang TT; Gulati S; Chou TC; Colvin M; Clarkson B
Cancer Res; 1987 Jan; 47(1):119-22. PubMed ID: 3466686
[TBL] [Abstract][Full Text] [Related]
25. Modulation of etoposide (VP-16) cytotoxicity by verapamil or cyclosporine in multidrug-resistant human leukemic cell lines and normal bone marrow.
Chao NJ; Aihara M; Blume KG; Sikic BI
Exp Hematol; 1990 Dec; 18(11):1193-8. PubMed ID: 2226679
[TBL] [Abstract][Full Text] [Related]
26. Density-gradient separation for 4-hydroperoxycyclophosphamide purging of autologous bone marrow grafts.
Rowley S; Davis J; Braine H; Jones R; Yeager A; Saral R; Santos G
Prog Clin Biol Res; 1990; 333():369-77. PubMed ID: 2308991
[TBL] [Abstract][Full Text] [Related]
27. Efficacy of a combined treatment with ASTA-Z 7654 and VP16-213 in vitro in eradicating clonogenic tumor cells from human bone marrow.
De Fabritiis P; Pulsoni A; Sandrelli A; Simone F; Amadori S; Meloni G; Mandelli F
Bone Marrow Transplant; 1987 Oct; 2(3):287-98. PubMed ID: 3502785
[TBL] [Abstract][Full Text] [Related]
28. In vitro chemoseparation of leukemic cells from murine bone marrow using VP16-213: importance of stem cell assays.
Stiff PJ; Koester AR
Exp Hematol; 1987 Mar; 15(3):263-8. PubMed ID: 3545881
[TBL] [Abstract][Full Text] [Related]
29. Use of long-term human marrow cultures to demonstrate progenitor cell precursors in marrow treated with 4-hydroperoxycyclophosphamide.
Winton EF; Colenda KW
Exp Hematol; 1987 Jul; 15(6):710-4. PubMed ID: 3595769
[TBL] [Abstract][Full Text] [Related]
30. Proliferative response of human marrow myeloid progenitor cells to in vivo treatment with granulocyte colony-stimulating factor alone and in combination with interleukin-3 after autologous bone marrow transplantation.
Lemoli RM; Fortuna A; Fogli M; Gherlinzoni F; Rosti G; Catani L; Gozzetti A; Miggiano MC; Tura S
Exp Hematol; 1995 Dec; 23(14):1520-6. PubMed ID: 8542941
[TBL] [Abstract][Full Text] [Related]
31. Purging in autologous hematopoietic stem cell transplantation using adenosine triphosphate (ATP) and 4-hydroperoxycyclophosphamide (4-HC).
Hatta Y; Itoh T; Baba M; Miyajima T; Shimojima H; Sawada U; Horie T
Leuk Res; 2002 May; 26(5):477-82. PubMed ID: 11916522
[TBL] [Abstract][Full Text] [Related]
32. Effect of combined treatment with interleukin-3 and interleukin-6 on 4-hydroperoxycyclophosphamide-mediated reduction of glutathione levels and cytotoxicity in normal and leukemic bone marrow progenitor cells.
Bhalla K; Bullock G; Lutzky J; Holladay C; Ibrado AM; Jasiok M; Singh S
Leukemia; 1992 Aug; 6(8):814-9. PubMed ID: 1640734
[TBL] [Abstract][Full Text] [Related]
33. In vitro purging of human rhabdomyosarcoma cells using 4-hydroperoxycyclophosphamide.
Ozkaynak MF; Nolta J; Parkman R
Cancer Res; 1990 Mar; 50(5):1455-8. PubMed ID: 2302710
[TBL] [Abstract][Full Text] [Related]
34. Density-gradient separation of autologous bone marrow grafts before ex vivo purging with 4-hydroperoxycyclophosphamide.
Rowley SD; Davis JM; Piantadosi S; Jones RJ; Yeager AM; Santos GW
Bone Marrow Transplant; 1990 Nov; 6(5):321-7. PubMed ID: 2291993
[TBL] [Abstract][Full Text] [Related]
35. Preclinical studies of the combination of mafosfamide (Asta-Z 7654) and etoposide (VP-16-213) for purging leukemic autologous marrow.
Tamayo E; Hervé P
Exp Hematol; 1988 Feb; 16(2):97-101. PubMed ID: 3276544
[TBL] [Abstract][Full Text] [Related]
36. Thy-1 antigen expression by murine high-proliferative capacity hematopoietic progenitor cells. I. Relation between sensitivity to depletion by Thy-1 antibody and stem cell generation potential.
Boswell HS; Wade PM; Quesenberry PJ
J Immunol; 1984 Dec; 133(6):2940-9. PubMed ID: 6149245
[TBL] [Abstract][Full Text] [Related]
37. Hematopoietic stem cell deficit of transplanted bone marrow previously exposed to cytotoxic agents.
Neben S; Hellman S; Montgomery M; Ferrara J; Mauch P
Exp Hematol; 1993 Jan; 21(1):156-62. PubMed ID: 8435103
[TBL] [Abstract][Full Text] [Related]
38. Potential drugs for elimination of acute lymphatic leukemia cells from autologous bone marrow.
Blaauw A; Spitzer G; Dicke K; Drewinko B; Vellekoop L; Zander A
Exp Hematol; 1986 Aug; 14(7):683-8. PubMed ID: 2426131
[TBL] [Abstract][Full Text] [Related]
39. Combined ex vivo treatment with immunotoxins and mafosfamid: a novel immunochemotherapeutic approach for elimination of neoplastic T cells from autologous marrow grafts.
Uckun FM; Stong RC; Youle RJ; Vallera DA
J Immunol; 1985 May; 134(5):3504-15. PubMed ID: 3884712
[TBL] [Abstract][Full Text] [Related]
40. Plasma interacts with mafosfamide toxicity to normal haematopoietic progenitor cells: impact on in vitro marrow purging.
Giarratana MC; Gorin NC; Douay L
Nouv Rev Fr Hematol (1978); 1995; 37(2):125-30. PubMed ID: 7644349
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]